Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal 5-FU for CIN2/3 in HIV-positive Women
NCT05362955Phase 1Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil in cervical intraepithelial neoplasia (CIN), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Safety of intravaginal 5-FU at 5 months. Started Apr 2023; status: completed.
02
Drugs
fluorouracil
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT05362955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362955.